share_log

In8bio | 424B5: Prospectus

In8bio | 424B5: Prospectus

In8bio | 424B5：募资说明书
美股sec公告 ·  05/07 16:14
Moomoo AI 已提取核心信息
In8bio has filed a prospectus supplement with the Securities and Exchange Commission, amending its previous prospectus dated November 21, 2022. The supplement, dated May 7, 2024, allows for the offer and sale of up to $8,900,000 of In8bio's common stock under a Controlled Equity Offering with Cantor Fitzgerald & Co. as the Sales Agent. To date, In8bio has sold 8,392,204 shares for gross proceeds of approximately $15.9 million. The company is limited by General Instruction I.B.6 of Form S-3 in the amount it can sell, which currently stands at an aggregate offering price of up to $8,900,000, considering the current public float. In8bio's common stock is traded on the Nasdaq Global Market under the symbol 'INAB'. The market value of non-affiliate held common stock was $41.5 million as of May...Show More
In8bio has filed a prospectus supplement with the Securities and Exchange Commission, amending its previous prospectus dated November 21, 2022. The supplement, dated May 7, 2024, allows for the offer and sale of up to $8,900,000 of In8bio's common stock under a Controlled Equity Offering with Cantor Fitzgerald & Co. as the Sales Agent. To date, In8bio has sold 8,392,204 shares for gross proceeds of approximately $15.9 million. The company is limited by General Instruction I.B.6 of Form S-3 in the amount it can sell, which currently stands at an aggregate offering price of up to $8,900,000, considering the current public float. In8bio's common stock is traded on the Nasdaq Global Market under the symbol 'INAB'. The market value of non-affiliate held common stock was $41.5 million as of May 7, 2024, based on a closing price of $1.30 per share on March 8, 2024. In the past 12 months, In8bio has sold $4,926,024 worth of securities under the same instruction. The company cautions that investing in its securities involves high risk, advising investors to review the 'Risk Factors' section in the Prior Prospectus and its most recent financial reports.
In8bio已向美国证券交易委员会提交了招股说明书补充文件，修订了其先前于2022年11月21日的招股说明书。该补编日期为2024年5月7日，允许以坎托·菲茨杰拉德公司为销售代理的受控股权发行，发行和出售In8Bio高达890万美元的普通股。迄今为止，In8Bio已出售了8,392,204股股票，总收益约为1,590万美元。该公司可出售的金额受到S-3表格I.B.6号一般指令的限制，考虑到目前的公众持股量，该公司的总发行价最高为8,900,000美元。In8bio的普通股在纳斯达克全球市场上市，股票代码为 “INAB”。根据2024年3月8日每股1.30美元的收盘价，截至2024年5月7日，非关联公司持有的普通股的市值为4,150万美元。在过去的12个月中，In8Bio根据同一指令出售了价值4,926,024美元的证券。该公司警告说，投资其证券涉及高风险，建议投资者查看先前招股说明书及其最新财务报告中的 “风险因素” 部分。
In8bio已向美国证券交易委员会提交了招股说明书补充文件，修订了其先前于2022年11月21日的招股说明书。该补编日期为2024年5月7日，允许以坎托·菲茨杰拉德公司为销售代理的受控股权发行，发行和出售In8Bio高达890万美元的普通股。迄今为止，In8Bio已出售了8,392,204股股票，总收益约为1,590万美元。该公司可出售的金额受到S-3表格I.B.6号一般指令的限制，考虑到目前的公众持股量，该公司的总发行价最高为8,900,000美元。In8bio的普通股在纳斯达克全球市场上市，股票代码为 “INAB”。根据2024年3月8日每股1.30美元的收盘价，截至2024年5月7日，非关联公司持有的普通股的市值为4,150万美元。在过去的12个月中，In8Bio根据同一指令出售了价值4,926,024美元的证券。该公司警告说，投资其证券涉及高风险，建议投资者查看先前招股说明书及其最新财务报告中的 “风险因素” 部分。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息